Serotonergic nerve endings

This neurotoxin produced permanent destruction to serotonergic nerve endings and fibers. 

Pharmacology Tetracyclics enhance central noradrenergic and serotonergic activity. They do not inhibit monoamine oxidase. Although maprotiline and mirtazapine are in the same chemical class, they each affect different neurotransmitters and thus have different side effect profiles. Maprotiline primarily acts by blocking reuptake of norepinephrine at nerve endings. 

The major pharmacological action of ecstasy involves its effect on the release of neurotransmitters from nerve endings in the brain particularly serotonin and dopamine. More prolonged effects (particularly following repeated doses) involve a loss of serotonin from fhe brain also a loss of serotonergic neuronal structures. It is unclear if any ofher neurofransmitter sysfems are involved. 

The intrinsic primary afferent neurons are present in both the myenteric and submucosal plexuses. They respond to luminal chemical stimuli, to mechanical deformation of the mucosa, and to stretch. The nerve endings of the primary afferent neurons can be activated by endogenous substances (e.g., serotonin) arising from local enterochromaffin cells or possibly from serotonergic nerves. 

Reuptake inhibitor An indirectly acting drug that increases the activity of transmitters in the synapse by inhibiting their reuptake into the presynaptic nerve ending. May act selectively on noradrenergic, serotonergic, or both types of nerve endings... 

---